NCT06104228View on ClinicalTrials.gov

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

March 31, 2026

Conditions
Pulmonary Arterial HypertensionIdiopathic Pulmonary Arterial HypertensionPulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder)Connective Tissue Diseases
Interventions
DRUG

129Xe Hyperpolarized

Each xenon dose will be limited to a volume less than 25% of a subject's total lung capacity (TLC), as is the case for all protocols currently carried out under IND 109490

Trial Locations (1)

27710

RECRUITING

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

American Heart Association

OTHER

lead

Bastiaan Driehuys

OTHER